Long
Under Major revaluation
Wouldn't be surprised to see this stock break all time highs in next few months and in the next 12-months $50+.
* Key notes: 2nd generation Covid Vaccine sponsored by NIAID that's being conducted through infectious diseases clinical research consortium (IDCRC). Established collaboration with Gilead Sciences to develop a vaccine-based immunotherapy as part of Gilead's efforts to find a 'curative treatment for human immunodeficiency virus" (HIV) infection, and received $60 million in proceeds as part of the collaboration for GRTS HIV candidate. More candidates in clinic on their website.
Very bullish accumulation going on after test of $35 (red horizontal line).
See my other picks! KKMPH $VBIV
BCRX GGRTS
Disclaimer: This is not a buy or sell recommendation. I am not a financial analyst. This information should be used for educational purposes only.
* Key notes: 2nd generation Covid Vaccine sponsored by NIAID that's being conducted through infectious diseases clinical research consortium (IDCRC). Established collaboration with Gilead Sciences to develop a vaccine-based immunotherapy as part of Gilead's efforts to find a 'curative treatment for human immunodeficiency virus" (HIV) infection, and received $60 million in proceeds as part of the collaboration for GRTS HIV candidate. More candidates in clinic on their website.
Very bullish accumulation going on after test of $35 (red horizontal line).
See my other picks! KKMPH $VBIV
BCRX GGRTSDisclaimer: This is not a buy or sell recommendation. I am not a financial analyst. This information should be used for educational purposes only.
Pubblicazioni correlate
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.
Pubblicazioni correlate
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.